Get started
Author

Ming Zhou

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial
2024 · Shun Lu, Wei Zhang, et al. · JAMA · 468
Ivonescimab Plus Chemotherapy in Non–Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial
2024 · HARMONi-A Study Investigators, Wenfeng Fang, et al. · JAMA · 259
PDF
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2025 · Anwen Xiong, Lei Wang, et al. · The Lancet · 210
AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial
2023 · Yuanyuan Zhao, Gang Chen, et al. · EClinicalMedicine · 129
PDF
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
2024 · Hua Zhong, Shengjie Sun, et al. · The Lancet Respiratory Medicine · 75
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2025 · Zhiwei Chen, Fang Yang, et al. · The Lancet · 63
Evidence for nontraditional mcr -containing archaea contributing to biological methanogenesis in geothermal springs
2023 · Jiajia Wang, Yan-Ni Qu, et al. · Science Advances · 32
PDF
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
2026 · Shun Lu, Baogang Liu, et al. · The Lancet · 24
A phase II study of AK112 (PD-1/VEGF bispecific) in combination with chemotherapy in patients with advanced non-small cell lung cancer.
2022 · Yuangyuan Zhao, Wenfeng Fang, et al. · Journal of Clinical Oncology · 22
Preliminary result of mixed bacterial vaccine as adjuvant treatment of hepatocellular carcinoma
1991 · Zhao You Tang, Hai Yan Zhou, et al. · Medical Oncology and Tumor Pharmacotherapy · 22
Comparable survival outcomes in HLA-Matched and haploidentical hematopoietic stem cell transplantation for severe aplastic anemia patients aged 40–50: A CBMTR Registry-based propensity score matching analysis over the last decade
2025 · Zheng-Li Xu, Yu-Ping Zhang, et al. · Cancer Letters · 19
Expert consensus on treatment for stage III non‐small cell lung cancer
2023 · Yi‐Long Wu, Shun Lu, et al. · Medicine Advances · 18
PDF
Profiling the impact of the promoters on CRISPR-Cas12a system in human cells
2023 · Jinhe Li, Qinchun Liang, et al. · Cellular & Molecular Biology Letters · 10
PDF
Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK.
2023 · Li Zhang, Wenfeng Fang, et al. · Journal of Clinical Oncology · 9
PDF
Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects
2024 · Wei Wang, Shengnan Zhang, et al. · BioDrugs · 2
Correction: Profiling the impact of the promoters on CRISPR-Cas12a system in human cells
2023 · Jinhe Li, Qingchun Liang, et al. · Cellular & Molecular Biology Letters · 2
PDF
A three-arm clinical study to compare pharmacokinetic and pharmacodynamic similarity of the denosumab biosimilar LY06006 with reference denosumab in healthy male subjects
2024 · Rainard Fuhr, Xuejiao Sun, et al. · Expert Opinion on Drug Metabolism & Toxicology · 1
PDF
Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study
2026 · Zhiwei Chen, Fang Yang, et al. · Future Oncology
Conversion surgery following immuno-chemotherapy in initially-unresectable esophageal squamous cell carcinoma: A real-world multicenter study.
2022 · Shujie Huang, Hansheng Wu, et al. · Journal of Clinical Oncology
Works count: 19
Citation count: 1,365
H-index: 12
I10-index: 13
Year
Topic
Type